The Phase III Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine
CHENGDU, China, April 5, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced that the prestigious medical journal Nature Medicine has published the results from the Phase III trial of its independently developed IL-4Rα antibody stapokibart, for the treatment of moderate-to-severe seasonal allergic rhinitis (SAR). The study, led by Professor Luo Zhang of Beijing Tongren Hospital, Capital Medical University, represents the world's first clinical report on an IL-4Rα-targeted biologic for SAR, underscoring Chinese scientists' pioneering role in allergic rhinitis innovation.
The study demonstrated that stapokibart significantly alleviates clinical symptoms and improves quality of life in patients with moderate-to-severe SAR who remained inadequately controlled despite standard therapies. This breakthrough offers a transformative solution to a global health challenge, ushering in a new era of biologic treatments for allergic rhinitis and providing hope to hundreds of millions of patients worldwide.
Innovative Mechanism Addresses Urgent Clinical Needs
Allergic rhinitis (AR), a chronic inflammatory disease of the nasal mucosa, is triggered by environmental allergens in sensitized individuals. In recent years, its global prevalence has risen significantly. Despite standard therapies, over 50% of patients continue to experience inadequately controlled symptoms, a substantial unmet need that severely impacts quality of life and imposes a heavy socioeconomic burden, positioning AR as a critical public health challenge.
The persistence and exacerbation of AR symptoms are primarily driven by amplified type 2 inflammatory cascades. Stapokibart, targeting the IL-4 receptor alpha subunit (IL-4Rα), dual-blocks both IL-4 and IL-13 signaling pathways. Through a multi-pronged approach—inhibiting T-cell activation and proliferation, suppressing B-cell activation and IgE synthesis, and reducing inflammatory cell infiltration—Stapokibart comprehensively attenuates allergic reactions, providing a novel therapeutic strategy for seasonal allergic rhinitis, and other type 2-mediated allergic diseases.
The First and Only Approved IL-4Rα Antibody Globally with Demonstrated Efficacy and Safety
Results of this phase III trial demonstrated that stapokibart rapidly, significantly, and sustainably controlled both nasal and ocular symptoms in patients with moderate-to-severe SAR, while markedly improving quality of life and maintaining a favorable safety profile.
Rapid, potent and sustained control of nasal symptoms:
Rapid relief of nasal obstruction: Compared to placebo group, patients in stapokibart group achieved significantly greater improvement in nasal congestion symptom at Day 2. By Day 7, 72% of patients reported clear nasal breathing, with the cumulative response rate rising to 86% at Week 2 and 94% at Week 4.
Potent and sustained control of nasal symptoms: Stapokibart demonstrated a 2.7-point reduction in daily reflective total nasal symptom score (rTNSS) from baseline by Day 4, significantly greater than the improvement in the placebo group.
Over the 2-week treatment period, stapokibart achieved a 3.6-point reduction in daily rTNSS from baseline, with a least squares (LS) mean difference of -1.3 points vs. placebo (the primary efficacy endpoint). Additionally, 62% of patients achieved mild or no symptom (defined as rTNSS ≤1 point for each symptom); Over the 4-week treatment period, the stapokibart group showed a 4.9-point reduction in daily rTNSS from baseline, with an LS mean difference of -1.7 points vs. placebo. The proportion of patients achieving mild or no nasal symptoms reached 84%.
Sustained and significant improvement of ocular symptoms:
Stapokibart demonstrated clinically significant reductions in the daily reflective Total Ocular Symptom Score (rTOSS) from baseline, with improvements of 2.6 points at week 2 and 3.7 points at week 4 respectively, both significantly superior to placebo. By Week 2, 62% of patients achieved mild or no ocular symptoms (defined as rTOSS ≤1 point for each symptom), increasing to 94% by Week 4.
Significant reduction in levels of type 2 inflammatory biomarkers
During the 4-week treatment period, the stapokibart group demonstrated significant reductions in total serum IgE levels and allergen-specific IgE (sIgE) levels against pollen allergens.
Additionally, stapokibart reduced type 2 inflammatory biomarker levels in nasal secretions, including cystatin SN (CST1) and eotaxin-3, demonstrating its dual mechanism of action: targeting both the underlying etiology (type 2 inflammation) and symptomatic manifestations of allergic rhinitis.
Safety
Stapokibart demonstrated a favorable safety profile in patients with seasonal allergic rhinitis. The incidence of treatment-emergent adverse events (TEAEs) was comparable to placebo, and no serious adverse events (SAEs) were reported during the trial.
Groundbreaking Research Ushers in a New Era of Biologic Therapy for Allergic Rhinitis
The PHECDA trial pioneered targeted biologic therapy for allergic rhinitis. The results supported the approval of stapokibart—the world's first and only IL-4Rα monoclonal antibody for seasonal allergic rhinitis (SAR)— by China's National Medical Products Administration (NMPA) on February 7, 2025. This breakthrough provides a novel therapeutic option for patients with moderate-to-severe refractory SAR, solidifying Chinese clinical scientists' global leadership in allergic rhinitis research and setting a precedent for future clinical development.
Stapokibart, a Category 1 New Drug independently developed by Keymed, is China's first domestically developed and one of the only two approved IL-4Rα antibody drugs worldwide. Since its initial NMPA approval in September 2024, stapokibart has secured three indications, including moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyposis(CRSwNP), and SAR, within six months, addressing critical unmet needs. With spring—the peak season for SAR—approaching, stapokibart offers patients a novel treatment leveraging its precision targeting of type 2 inflammation and robust clinical efficacy.
Keymed focuses on high-value unmet medical needs, delivering high-quality, accessible, and innovative therapies for patients globally. The company has now established a diverse proprietary R&D platform and a differentiated pipeline with industry-leading candidates. With a comprehensive biopharmaceutical industry layout spanning from molecular discovery to commercial-scale production, Keymed is accelerating the availability of transformative medicines.
About Stapokibart
Stapokibart (CM310) is a high-efficient, humanized antibody targeting the interleukin-4 receptor alpha subunit (IL-4Rα), and is the first domestically manufactured IL-4Rα antibody drug granted marketing approval by the NMPA. By targeting IL-4Rα, Stapokibart can block both interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling. IL-4 and IL-13 are two key cytokines trigger type II inflammation. Stapokibart has demonstrated a favorable safety profile and encouraging efficacy across multiple clinical trials and has been approved for marketing for the treatment of moderate to severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyposis, and Seasonal Allergic Rhinitis in September 2024, December 2024 and February 2025, respectively.
About Keymed Biosciences Inc.
Keymed Biosciences Inc. (HKEX: 02162) focuses on the urgent unmet clinical needs and is committed to providing high-quality, affordable, innovative therapies for patients in China and overseas. Keymed was founded by medical and scientific experts who have strong experience in the transformation of scientific and technological achievements to commercialization at home and abroad.
View original content:https://www.prnewswire.com/news-releases/the-phase-iii-study-data-of-stapokibart-for-seasonal-allergic-rhinitis-published-in-nature-medicine-302421457.html
SOURCE Keymed Biosciences
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
13 hours ago
- The Hill
Thanks to imported drugs, America has lost control of its medicine cabinet
America is facing a growing crisis in its medical system — not from a lack of talent or innovation, but from a breakdown in the control, safety and supply of essential medicines. Our growing reliance on imports is now driving serious drug shortages, destabilizing supply chains and increasingly making medications unsafe. At the root of it is a hard truth: We no longer have control of the medicines we depend on every day. In 2002, America manufactured 83.7 percent of the pharmaceuticals it consumed. By 2024, that number had dropped to just 37.1 percent. Meanwhile, the U.S. pharmaceutical trade deficit has soared, reaching a record $118.3 billion in 2024. We didn't just outsource manufacturing — we outsourced the sovereignty and safety of our health care system. This means that nearly two-thirds of America's pharmaceutical supplies are now imported. Most critical medications, such as generic drugs, now come from China and India. China controls 80 to 90 percent of the global supply of active pharmaceutical ingredients — the chemical building blocks of modern medicine. Even drugs labeled 'Made in the USA' often chemically originate in China. And India, which produces about half of America's finished generic drugs, relies on China for up to 80 percent of its active pharmaceutical not a supply chain — it's a ticking time something goes wrong, American patients suffer. In 2023, the Food and Drug Administration shut down a single Indian plant responsible for 50 percent of the U.S. supply of cisplatin, a critical chemotherapy drug, after uncovering a 'cascade of failure' in safety practices and shredded documents soaked in acid. With no domestic backup, patients nationwide had their treatments delayed. That wasn't a fluke. 40 percent of U.S. generic drugs have only one FDA-approved manufacturer. Because of that single chokepoint, when one factory fails, the whole system can crack. We are now seeing widespread drug shortages across the medical system. Hospital pharmacists report an average of 301 critical drug shortages at any given time. And 85 percent say these shortages are moderately or critically affecting care. Doctors often lack crucial medicines such as antibiotics, sedatives and cancer drugs. These aren't obscure drugs. They're foundational medicines. But America no longer makes them. Even when imported drugs do arrive, they're not always safe. A 2025 study found that Indian generics are 54 percent more likely to cause serious side effects than their U.S.-made counterparts. Indian factory violations have also been tied to at least eight U.S. patient deaths. China's record is equally disturbing. In 2008, dozens of Americans died after receiving contaminated heparin from Chinese suppliers. This isn't what the American people want. In a national survey, 85 percent of hospital pharmacists said they would pay more for safer generics. But under today's rules, price overshadows quality. Hospitals have little oversight of drug quality — and foreign producers face few consequences for cutting corners. Even the federal government is flying blind. A 2023 Department of Defense review found that 22 percent of essential military-use drugs had unknown ingredient sourcing. That's a national security April, the Trump administration took a necessary step by launching an investigation into generic pharmaceutical imports that correctly frames the issue as a national security threat. But that recognition alone isn't enough. To address this crisis, Washington should impose targeted tariffs on generic drugs from adversarial nations. It must also rebuild domestic pharmaceutical production through tax credits and long-term contracts. America urgently needs full transparency in drug labeling to disclose where drugs and their ingredients are made. The FDA must step up — with stronger enforcement abroad and a ban on imports from repeat safety violators. And to secure critical ingredients during market disruptions, Washington must pursue a long-term vision that includes a 'strategic pharmaceutical reserve.' This isn't just protectionism. It's a restoration of America's medical security. No nation can call itself sovereign if it can't produce its own medicines, and no patient is safe if their health care depends on quality control in a factory 8,000 miles decades, we were told that offshoring production would make things cheaper, smoother and more efficient. But America can no longer depend on unstable foreign suppliers. It's time to restore our pharmaceutical independence and take back control of our medicine cabinet. Andrew Rechenberg is an economist at the Coalition for a Prosperous America.
Epoch Times
a day ago
- Epoch Times
How Women Can Prevent Hair Loss by Nourishing the Liver and Kidneys
Hair health reflects overall physical well-being. Women often experience hair loss due to various causes, including postpartum recovery, menopause, alopecia areata, or scalp issues such as itchiness and dandruff, exacerbated by summer heat. Traditional Chinese medicine (TCM) offers a holistic approach, emphasizing a blend of targeted dietary supplements, meticulous scalp care, and proper hair-washing techniques to reduce hair loss effectively. Dr. Chen Hsin-hung, a TCM practitioner at Hanyitang Chinese Medicine clinics in Taiwan, shared a case of hair loss. A woman in her 20s developed alopecia areata (patchy baldness) after receiving the COVID-19 vaccine, which left her deeply distressed when her hair almost entirely fell out. Through 6 to 8 months of TCM treatment, she regrew dark, vibrant hair. Exploring Hair Loss Causes With TCM From the perspective of TCM, the liver and kidneys are closely related to hair health as they play a vital role in the internal organ-centered energy system.
New York Post
2 days ago
- New York Post
My Chinese mom's timeless health tips — including a ‘magic' go-to and a plant that helps with cramps, colds, and upset stomachs
Modern health trends come and go, but the real secret to feeling your best may lie in ancient practices you can do right at home. 'So many of my wellness roots trace back to my mom's kitchen. She always believed that food is medicine and that healing starts long before you're sick,' Lulu Ge, founder of Elix, a wellness brand inspired by Traditional Chinese Medicine (TCM), told The Post. Ge shared three of her mother's time-tested food tips, plus two bonus remedies, to help you spend less time in the doctor's office and more time enjoying your life. 5 Lulu Ge notes that traditional Chinese medicine focuses on whole-body wellness. Courtesy of Elix Healing Keep it warm to beat the cramps Ladies, listen up: 'Eat warming foods for a warm, pain-free womb,' Ge said. That means ditching iced drinks, especially during your period. In TCM, the menstrual cycle is believed to be closely linked to the flow of 'Qi,' or vital energy, and blood. Ge's mother warned that getting chilled can cause stagnation, leading to painful cramps, irregular periods and trouble shedding the uterine lining. The remedy? Load up on warming spices and cooked foods, while avoiding cold and raw dishes, to keep your blood flowing and stay pain-free. Ginger to the rescue Used in Chinese and Indian medicine for thousands of years, ginger comes from the root of the Zingiber officinale plant. 5 Ginger can reduce bloating and support digestion. Luis Echeverri Urrea – 'It's a warming spice shown to help with digestive issues, nausea, and bloating,' Ge said. Here's how it works: ginger speeds up the rate at which food leaves the stomach, which helps those with delayed stomach emptying — a common cause of nausea. It also reduces fermentation, constipation and other causes of bloating and gas. Additionally, ginger contains gingerol, a compound with powerful antioxidant and anti-inflammatory effects. These help reduce inflammation in the digestive tract, easing stomach pain and cramps. Whenever Ge had cramps, a cold, or an upset stomach, her mother would simmer fresh ginger into tea and insist she sip it slowly. 'Now, I keep Elix's Ginger Aide with me everywhere as a nod to that tradition,' she said. The product is a pure concentrate of decocted organic ginger slices that allows users 'to feel the effects of plant medicine in a gentle, daily ritual.' Broth that heals Bone broth isn't just soup — it's liquid gold. Made by simmering animal bones for hours, it's packed with collagen, minerals and amino acids. 5 Bone broth is made from animal bones and connective tissue, typically cattle, chicken or fish. qwartm – 'Bone broth = magic,' Ge said. 'It was the go-to for recovery — after illness or just when life felt depleting.' In TCM, bone broth is a powerhouse elixir that boosts Qi, blood and 'Yin' energy, which is responsible for providing the body with the moisture it needs to function properly. When yin is low, you may experience symptoms such as dry skin, night sweats, constipation and anxiety. Qi deficiency often manifests as fatigue, weakness, shortness of breath and loss of appetite. In TCM, bone broth is also often used to nourish postpartum mothers, giving them the nutrients and energy needed to recover from childbirth and support lactation. Ge said her mother always paired bone broth with goji berries, red dates and, of course, a dash of love. The power of rest In TCM, wellness isn't just about what's on your plate. 'My mom made sure I prioritized sleep and restorative 'Yin' time for rest and relaxation,' Ge said, noting this is especially crucial during your period, when you're wiped out or feeling on the verge of getting sick. 'She saw rest as a form of healing — not a luxury, but a necessity. It helps you bounce back with fresh energy and focus,' Ge added. 5 About 84 million Americans don't consistently get the recommended amount of sleep for optimal health. Syda Productions – In the US, about 1 in 3 adults regularly miss out on the sleep they need to stay healthy, according to a 2022 Gallup poll. Adequate sleep is essential for physical and mental well-being, enabling the brain and body to undergo critical repair and restoration processes. These include muscle recovery, tissue growth, and hormone regulation, as well as the removal of toxins, support of immune function and memory consolidation. Skip the pills — try this first 'Anytime I had pain, her instinct was to reach for a warming balm, acupressure point or herbal patch first,' Ge said. 'She trusted the body could heal — with the right support.' 5 Ge recommends blending Eastern and Western approaches for optimal health. Courtesy of Elix Healing TCM treats the whole person, aiming to fix root problems, not just mask symptoms like Western medicine often does. Herbal patches and balms work by delivering healing directly through the skin to sore spots, cutting down on systemic side effects and targeting the pain where it hurts most. In TCM, your skin mirrors is also thought to mirror your inner health. These external remedies help strengthen and repair it, making you tougher against the daily grind. Plus, balms and patches team up with internal herbs for a one-two punch, tackling symptoms and restoring balance throughout the body's energy system. All these tips can boost your health — but don't ditch Western medicine just yet. 'The real power lies in blending Eastern and Western medicine,' Ge said. 'Western tools for acute issues and diagnostics, TCM for long-term support, prevention and personalized care. Together, they offer something truly holistic,' she explained.
